Back to Search Start Over

Intra-Anal Imiquimod Cream against Human Papillomavirus Infection in Men Who Have Sex with Men Living with HIV: A Single-Arm, Open-Label Pilot Study

Authors :
Durukan, D
Phillips, TR
Murray, GL
Ong, JJ
Grulich, AE
Poynten, IM
Jin, F
Bradshaw, CS
Aguirre, I
Silvers, J
Kent, H
Atchison, S
Balgovind, P
Cornall, A
Chen, MY
Fairley, CK
Chow, EPF
Durukan, D
Phillips, TR
Murray, GL
Ong, JJ
Grulich, AE
Poynten, IM
Jin, F
Bradshaw, CS
Aguirre, I
Silvers, J
Kent, H
Atchison, S
Balgovind, P
Cornall, A
Chen, MY
Fairley, CK
Chow, EPF
Publication Year :
2021

Abstract

Men who have sex with men (MSM) living with HIV have a high prevalence and incidence of anal high-risk human papillomavirus (hrHPV) and anal cancer. We conducted an open-label, single-arm pilot study to examine the tolerability of imiquimod cream among MSM aged ≥18 years, living with HIV, who tested positive for anal hrHPV at Melbourne Sexual Health Centre between April 2018 and June 2020. We instructed men to apply 6.25 mg imiquimod intra-anally and peri-anally 3 doses per week for 16 weeks (period 1) and then one dose per week for a further 48 weeks (period 2). Twenty-seven MSM enrolled in period 1 and 24 (86%) applied at least 50% of doses. All men reported adverse events (AEs), including 39.5% grade 1, 39.5% grade 2, and 21% grade 3 AEs on at least one occasion. Eighteen MSM (67%) temporarily stopped using imiquimod during period 1, most commonly due to local AEs (n = 11) such as irritation and itching. Eighteen MSM continued in period 2 and all applied at least 50% of doses with no treatment-limiting AEs reported. Imiquimod 3 doses per week caused local AEs in most men and was not well tolerated. In contrast, once-a-week application was well tolerated over 48-weeks with no treatment-limiting AEs.

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1315699263
Document Type :
Electronic Resource